Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer

Bone Marrow Transplantation

Volumn 26, Issue 7, 2000, Pages 729-735

  Reece, D E ^a   Foon, K A ^b   Bhattacharya Chatterjee, M ^b   Hale, G A ^a   Howard, D S ^a   Munn, R K ^a   Nath, R ^a   Plummer, B A ^a   Teitelbaum, A ^c   Phillips, G L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Titan Pharmaceuticals Inc   (United States)

Author keywords

Anti idiotype breast cancer vaccine; Autologous stem cell transplantation; Metastatic breast cancer

Indexed keywords

ALUMINUM HYDROXIDE; AMIFOSTINE; ANTIIDIOTYPIC ANTIBODY; BOVINE SERUM ALBUMIN; CANCER ANTIBODY; CANCER VACCINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; ESTROGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MUCIN; PACLITAXEL; PREDNISONE; PROGESTERONE; SODIUM CHLORIDE; THIOTEPA; TRIAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AGED; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MYALGIA; PRIORITY JOURNAL; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0033754249     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702607     Document Type: Article

References (49)

1. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America
2. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, carboplatin
3. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
4. Immunotherapeutic approaches for the treatment of breast cancer
5. The immunology and immunotherapy of breast cancer: An update
6. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
7. Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
8. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC-1 tumor antigen for broadly applicable vaccine therapies
9. Vaccination of high-risk breast cancer patients (PTS) with MUC-1 (32aa) keyhole limpet hemocyanin (KLH) conjugate plus QS-21: Preliminary results
10. Phase I trial with ALVAC-CEA B7.1. In immunization in advanced CEA-expressing adenocarcinomas
11. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant
12. Speculations on idiotypes and homobodies
13. Towards a network theory of the immune system
14. Immunization of idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation
15. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice
16. Idiotypic immunization induced immunity to mutant p53 and tumor rejection induced by idiotypic immunization
17. Tumor-specific idiotype vaccines, IV. Analysis of the idiotypic network in tumor immunity
18. Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen
19. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta)
20. Tumor specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumor cells
21. Suppression of in vivo tumor formation induced by simian virus 40 transformed cells in mice receiving anti-idiotypic antibodies
22. Immunotherapy of murine sarcomas with auto- anti-idiotypic monoclonal anti-bodies which bind to tumor-specific T-cells
23. Immune response to carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
24. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
25. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK 2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma
26. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialo- ganglioside GD2
27. Induction of immune response in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors
28. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restrictive T-cell antigen
29. Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule
30. Immunotherapeutic preclinical evaluation of anti-human milk fat globule MoAbs Mc5 and BrE-1
31. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer
32. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer
33. Immune responses in patients with breast cancer treated with an anti-idiotype antibody that mimics the human milk fat globule (HMFG) antigen
34. High dose paclitaxel, cyclophosphamide and cisplatin with autologous progenitor support: A phase I trial
35. Acute effects of multiple doses of ethyol® (amifostine) [AF] plus high-dose paclitaxel (P), cyclophosphamide (CY), cisplatin (cDDP) and autologous stem cell transplantation (ASCT) in patients (PTS) with metastatic breast cancer
36. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
37. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
38. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of anti-idiotype antibody
39. Immune reconstitution and immunotherapy after autologous stem cell transplantation
40. Immune constitution after transplantation of autologous peripheral CD34+ cells: Analysis of predictive factors and comparison with unselected progenitor transplants
41. Autografting of highly purified peripheral blood progenitor cells following myeloblative therapy in patients with lymphoma: A prospective study of the long-term effects on tumor eradication, reconstitution of immune recovery
42. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
43. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
44. Evidence of a cellular immune response against Sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope-STn-KLH cancer vaccine
45. Counterpoint. Cancer vaccines: Single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine
46. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: Comparison with healthy age-matched controls
47. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
48. Anti-idiotype antibody vaccination in conjunction with intensive therapy (IT) and autologous stem cell transplantation (ASCT) for patients (PTS) with metastatic breast cancer